There are 2789 resources available
920P - The sarcopenia skeletal muscle mass index (SMI) has a three-tier survival effect in HNSCC, which can be predicted by hemoglobin (Hb), lymphocytes (Ly) and creatinine (Cre)
Presenter: Simona Guerriero
Session: ePoster Display
921P - Assessment of health-related quality of life in head and neck cancer patients treated with chemoradiation
Presenter: VINAYAKUMAR MUTTAGI
Session: ePoster Display
922P - Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world setting
Presenter: Michael Pogorzelski
Session: ePoster Display
923P - Nivolumab in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) progressing on/or after a platinum-based therapy: Interim analysis of a prospective French real-world study (ProNiHN)
Presenter: Christophe Le Tourneau
Session: ePoster Display
924P - HANNA: Effectiveness and quality-of-life data from a real-world study of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab in Germany
Presenter: Harald Müller-Huesmann
Session: ePoster Display
980P - Phase Ib study of a liposomal formulation of eribulin (E7389-LF) + nivolumab (Nivo) in patients (pts) with advanced solid tumors
Presenter: Noboru Yamamoto
Session: ePoster Display
981P - Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
Presenter: Sarwan Bishnoi
Session: ePoster Display
982P - A phase II study of SHR-1701 plus famitinib for patients with previously treated advanced pancreatic cancer or biliary tract cancer
Presenter: jing xie
Session: ePoster Display
983P - Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
Presenter: Nuria Kotecki
Session: ePoster Display
1771P - Identification and validation of tissue or ctDNA PTPRD phosphatase domains deleterious mutations as prognostic and predictive biomarkers for ICIs in non-squamous NSCLC
Presenter: Yiting Sun
Session: ePoster Display